Cure8 research brief
If you have ulcerative colitis and cannot tolerate 5-ASA (mesalamine), this study suggests you may be at higher risk of progressing to difficult-to-treat disease, particularly if your intolerance fits an acute intolerance syndrome (AIS) pattern.
Clinicians treating ulcerative colitis, researchers studying treatment response and drug intolerance, and adult patients with UC (especially those with suspected 5-ASA intolerance).
The study reviewed 919 UC patients and classified 145 (15.8%) as 5-ASA intolerant, distinguishing acute intolerance syndrome (AIS) from non-AIS phenotypes. Overall intolerance doubled the subdistribution hazard of progressing to D2T UC, while AIS showed a larger effect. Intolerance was not associated with higher colectomy risk.
Patients who remained on 5-ASA at 90 or 365 days had a lower cumulative incidence of D2T progression than non-users. What this means for care: The findings suggest that carefully characterizing 5-ASA intolerance, especially identifying AIS, may help clinicians stratify risk and consider individualized treatment plans.
This is observational data and does not by itself prove causation or prescribe a management change. Limitations: This is a retrospective cohort; residual confounding and treatment-selection biases are possible. The abstract-level source provides summary results but not full methodological detail.
This report is an abstract-based summary of a retrospective cohort from the Journal of Gastroenterology. Observational design means associations may not be causal; the study distinguishes intolerance phenotypes and used competing-risk analyses, but full methods and subgroup details are in the article.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declarations. Conflict of interest: The authors declare no conflict of interest.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Higher, optimised doses of prolonged-release mesalazine were linked with fewer clinical recurrences over 12 months in adults with mild-to-moderate UC, which could influence treatment decisions about mesalazine dose and...
For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...
This case report describes successful use of vedolizumab to treat severe UC in a patient who also had PSC and SLE — a rare and complex combination. Patients and clinicians may find it relevant when considering biologic...
